Huaan Securities released a research report on April 21 stating that it gave Zoli Pharmaceutical (300181.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 23 and 24Q1, continuous optimization of cost ratios, and continuous improvement in profitability; 2) continuous optimization of the cost ratio in 23, with impressive net interest rate optimization results; 3) the growth of the core product Wuling Series Q4 accelerated and is expected to maintain the trend in 2024. (Mainichi Keizai Shimbun)
华安证券4月21日发布研报称，给予佐力药业（300181.SZ）买入评级。评级理由主要包括：1）23年和24Q1业绩表现亮眼，费用率持续优化，盈利能力持续提升；2）23年费用率持续优化，净利率优化成果亮眼；3）核心产品乌灵系列Q4增长加速恢复，2024年有望维持趋势。（每日经济新闻）
Huaan Securities released a research report on April 21 stating that it gave Zoli Pharmaceutical (300181.SZ) a purchase rating. The main reasons for the rating include: 1) excellent performance in 23 and 24Q1, continuous optimization of cost ratios, and c
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated